Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

NCT04915183 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

224

Enrollment

NIH

Sponsor class

Conditions

Hearing Loss
Head and Neck Cancer

Interventions

OTHER: Placebo
DRUG: Atorvastatin

Sponsor

National Institute on Deafness and Other Communication Disorders (NIDCD)